Cailin Conner

DocwireNews

Hyperuricaemia, elevated levels of serum urate in the blood, leads to the formation of monosodium urate (MSU) crystals. MSU deposits in and around the joints, resulting in gout. If gout is uncontrolled, patients may experience frequent flares of inflammation and pain. To treat gout and mitigate the symptoms, urate-lowering therapies (ULT) are often prescribed to patients to lower their serum urate levels, and in turn, prevent painful gout flares. Prior <a href="https://onlinelibrary.wiley.com/doi/10.1002/art.41247" target="_blank" rel="noopener">studies</a> have reported that gout flares are frequent after beginning ULT, particularly 3 to 6 months after starting treatment.Gout flares can be triggered by a variety of things such as purine-rich diets and alcohol consumption. Increases in SU have also been observed in patients postoperatively who underwent bariatric surgery. While SU fluctuations can trigger gout flares, the evidence is lacking regarding the fluctuation in SU over time during ULT.Researchers at the Center for Treatment of Rheumatic and Musculoskeletal Diseases at Diakonhjemmet Hospital in Oslo, Norway, investigated the ways fluctuation and changes in SU during an intensive ULT approach were related to gout flares. The study, published in <a href="https://link.springer.com/article/10.1007/s10067-022-06416-4" target="_blank" rel="noopener">Clinical Rheumatology</a>, prospectively evaluated 173 patients with increased SU and a recent flare who were being treated with ULT over 1 year, with follow-up at 2 years.SU fluctuation was measured during each study visit, and was defined by the authors as &ldquo;the absolute sum of all observed SU changes between adjacent visits accumulated from baseline to time of observation.&rdquo; SU fluctuation and change were compared between patients with and without gout flares during the study period. The authors also examined the effect of larger SU changes between two consecutive visits with predefined thresholds of &gt;30 &micro;mol/L,&thinsp;&gt;60 &micro;mol/L, and&thinsp;&gt;90 &micro;mol/L change in SU levels.During the first year of the study period, 80.6% of patients experienced a gout flare, and 26.0% of patients experienced a gout flare during the second year. For patients with a gout flare, the sum of SU changes was higher compared with patients without a gout flare during year 1.&ldquo;No relation to flares was seen for SU changes between adjacent visits, and not whether patients after initially reaching the treatment target again increased SU towards levels with increased risk of MSU crystal formation,&rdquo; the authors said. &ldquo;We found thus that the sum of absolute SU changes over an observation period was a useful indicator of fluctuation, being associated with the occurrence of flare during year one.&rdquo;The authors also note that while &ldquo;Our findings require confirmation in other longitudinal studies,&rdquo; they concluded that, &ldquo;Findings support existing treatment recommendations with a focus on the gradual increase of ULT to lower SU and reinforce a need for treatment adherence to avoid SU fluctuation.&rdquo;

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Fluctuations of Serum Urate Levels in Gout Patients Over 2 Years

Nephrology Times

Hyperuricaemia, elevated levels of serum urate in the blood, leads to the formation of monosodium urate (MSU) crystals. MSU deposits in and around the joints, resulting in ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe